It's been a good week for PeptiDream Inc. (TSE:4587) shareholders, because the company has just released its latest quarterly results, and the shares gained 2.5% to JP¥1,065. Results look to have been somewhat negative - revenue fell 9.3% short of analyst estimates at JP¥5.6b, although statutory losses were somewhat better. The per-share loss was JP¥2.84, 59% smaller than the analysts were expecting prior to the result. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
Taking into account the latest results, the current consensus from PeptiDream's six analysts is for revenues of JP¥39.1b in 2027. This would reflect a major 91% increase on its revenue over the past 12 months. PeptiDream is also expected to turn profitable, with statutory earnings of JP¥61.90 per share. Before this earnings report, the analysts had been forecasting revenues of JP¥41.4b and earnings per share (EPS) of JP¥72.67 in 2027. The analysts seem less optimistic after the recent results, reducing their revenue forecasts and making a real cut to earnings per share numbers.
View our latest analysis for PeptiDream
It'll come as no surprise then, to learn that the analysts have cut their price target 5.2% to JP¥2,608. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. The most optimistic PeptiDream analyst has a price target of JP¥4,400 per share, while the most pessimistic values it at JP¥1,100. So we wouldn't be assigning too much credibility to analyst price targets in this case, because there are clearly some widely different views on what kind of performance this business can generate. As a result it might not be a great idea to make decisions based on the consensus price target, which is after all just an average of this wide range of estimates.
Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. It's clear from the latest estimates that PeptiDream's rate of growth is expected to accelerate meaningfully, with the forecast 68% annualised revenue growth to the end of 2027 noticeably faster than its historical growth of 8.2% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 29% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect PeptiDream to grow faster than the wider industry.
The Bottom Line
The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for PeptiDream. They also downgraded PeptiDream's revenue estimates, but industry data suggests that it is expected to grow faster than the wider industry. Furthermore, the analysts also cut their price targets, suggesting that the latest news has led to greater pessimism about the intrinsic value of the business.
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple PeptiDream analysts - going out to 2028, and you can see them free on our platform here.
Another thing to consider is whether management and directors have been buying or selling stock recently. We provide an overview of all open market stock trades for the last twelve months on our platform, here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.